Laboratory of Experimental Neurology and Neuroimmunology, 2nd Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Macedonia, Greece.
Exp Neurol. 2011 Jul;230(1):78-89. doi: 10.1016/j.expneurol.2011.02.021. Epub 2011 Apr 5.
Autologous bone marrow stromal cells (BMSCs) offer significant practical advantages for potential clinical applications in multiple sclerosis (MS). Based on recent experimental data, a number of clinical trials have been designed for the intravenous (IV) and/or intrathecal (ITH) administration of BMSCs in MS patients. Delivery of BMSCs in the cerebrospinal fluid via intracerebroventricular (ICV) transplantation is a useful tool to identify mechanisms underlying the migration and function of these cells. In the current study, BMSCs were ICV administered in severe and mild EAE, as well as naive animals; neural precursor cells (NPCs) served as cellular controls. Our data indicated that ICV-transplanted BMSCs significantly ameliorated mild though not severe EAE. Moreover, BMSCs exerted significant anti-inflammatory effect on spinal cord with concomitant reduced axonopathy only in the mild EAE model. BMSCs migrated into the brain parenchyma and, depending on their cellular density, within brain parenchyma formed cellular masses characterized by focal inflammation, demyelination, axonal loss and increased collagen-fibronectin deposition. These masses were present in 64% of ICV BMASC-transplanted severe EAE animals whereas neither BMSCs transplanted in mild EAE cases nor the NPCs exhibited similar behavior. BMSCs possibly exerted their fibrogenic effect via both paracrine and autocrine manner, at least partly due to up-regulation of connective tissue growth factor (CTGF) under the trigger of TGFb1. Our findings are of substantial relevance for clinical trials in MS, particularly regarding the possibility that ICV transplanted BMSCs entering the inflamed central nervous system may exhibit - under conditions - a local pathology of yet unknown consequences.
自体骨髓基质细胞(BMSCs)为多发性硬化症(MS)的多种潜在临床应用提供了重要的实际优势。基于最近的实验数据,已经设计了一些临床试验,用于向 MS 患者静脉内(IV)和/或鞘内(ITH)给予 BMSCs。通过脑室内(ICV)移植将 BMSCs 递送至脑脊液中是一种有用的工具,可以鉴定这些细胞迁移和功能的潜在机制。在当前的研究中,在严重和轻度 EAE 以及未处理的动物中,通过 ICV 给予 BMSCs;神经前体细胞(NPCs)作为细胞对照。我们的数据表明,ICV 移植的 BMSCs 可显著改善轻度 EAE,但不能改善严重 EAE。此外,BMSCs 在轻度 EAE 模型中对脊髓具有显著的抗炎作用,同时伴有轴突病变减轻。BMSCs 迁移到脑实质中,并根据其细胞密度,在脑实质中形成以局灶性炎症、脱髓鞘、轴突丢失和胶原蛋白纤维连接蛋白沉积增加为特征的细胞团块。在 64%的 ICV BMASC 移植的严重 EAE 动物中存在这些团块,而在轻度 EAE 病例中移植的 BMSCs 或 NPCs 均未表现出类似的行为。BMSCs 可能通过旁分泌和自分泌方式发挥其成纤维作用,至少部分原因是在 TGFb1 的触发下结缔组织生长因子(CTGF)的上调。我们的发现与 MS 的临床试验具有实质性的相关性,特别是关于 ICV 移植的 BMSCs 进入炎症性中枢神经系统的可能性,在某些条件下可能会表现出未知后果的局部病理。